[go: up one dir, main page]

UY31103A1 - Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones - Google Patents

Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones

Info

Publication number
UY31103A1
UY31103A1 UY31103A UY31103A UY31103A1 UY 31103 A1 UY31103 A1 UY 31103A1 UY 31103 A UY31103 A UY 31103A UY 31103 A UY31103 A UY 31103A UY 31103 A1 UY31103 A1 UY 31103A1
Authority
UY
Uruguay
Prior art keywords
microparticles
pharmaceutical compositions
analog
somatostatine
understanding
Prior art date
Application number
UY31103A
Other languages
English (en)
Inventor
Vitomir Vucenovic
Marc Riemenschnitter
Olivier Lambert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31103(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY31103A1 publication Critical patent/UY31103A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a micropartículas mejoradas que comprenden un análogo de somatostatina, a un proceso para la elaboración de estas micropartículas, y a composiciones farmacéuticas que las comprenden.
UY31103A 2007-05-24 2008-05-23 Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones UY31103A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07108796 2007-05-24

Publications (1)

Publication Number Publication Date
UY31103A1 true UY31103A1 (es) 2009-01-05

Family

ID=38222465

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31103A UY31103A1 (es) 2007-05-24 2008-05-23 Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones

Country Status (42)

Country Link
US (2) US20100178344A1 (es)
EP (2) EP3666263A1 (es)
JP (1) JP5507447B2 (es)
KR (2) KR20100017904A (es)
CN (1) CN101677965B (es)
AR (1) AR066677A1 (es)
AU (1) AU2008252931B2 (es)
BR (1) BRPI0811904A2 (es)
CA (1) CA2683935C (es)
CL (1) CL2008001509A1 (es)
CO (1) CO6241097A2 (es)
CR (1) CR11078A (es)
CU (1) CU24028B1 (es)
DK (1) DK2164473T3 (es)
DO (1) DOP2009000262A (es)
EA (1) EA018203B1 (es)
EC (1) ECSP099793A (es)
ES (1) ES2761227T3 (es)
GE (1) GEP20125582B (es)
GT (1) GT200900302A (es)
HN (1) HN2009003296A (es)
HU (1) HUE046490T2 (es)
IL (1) IL201571B (es)
MA (1) MA31445B1 (es)
ME (1) ME00955B (es)
MX (1) MX2009012536A (es)
MY (1) MY148915A (es)
NI (1) NI200900207A (es)
NZ (1) NZ580589A (es)
PA (1) PA8781501A1 (es)
PE (1) PE20090387A1 (es)
PL (1) PL2164473T3 (es)
PT (1) PT2164473T (es)
SI (1) SI2164473T1 (es)
SM (1) SMP200900099B (es)
SV (1) SV2009003421A (es)
TN (1) TN2009000447A1 (es)
TW (1) TWI412373B (es)
UA (1) UA97396C2 (es)
UY (1) UY31103A1 (es)
WO (1) WO2008142153A1 (es)
ZA (1) ZA200907168B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR057181A1 (es) * 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion
RU2403914C2 (ru) * 2009-03-27 2010-11-20 Федеральное государственное учреждение Московский научно-исследовательский онкологический институт им. П.А. Герцена Федерального агентства по высокотехнологичной медицинской помощи (ФГУ МНИОИ им. П.А. Герцена Росмедтехнологий) Способ выбора тактики послеоперационного лечения медуллярного рака щитовидной железы
US20120156304A1 (en) * 2010-12-15 2012-06-21 Thomas Tice Branched polyol polyesters, blends, and pharmaceutical formulations comprising same
PL3199146T3 (pl) 2011-04-25 2020-03-31 Shan Dong Luye Pharmaceutical Co., Ltd. Kompozycja mikrosfery rysperydonu o przedłużonym uwalnianiu
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
IN2014DN09831A (es) * 2012-05-25 2015-08-07 Camurus Ab
US10821200B2 (en) * 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
EP3339372A1 (en) * 2016-12-22 2018-06-27 Solvay SA Glycolic acid polymer composition
CN110870853B (zh) * 2018-08-29 2020-12-11 深圳翰宇药业股份有限公司 缓释帕瑞肽微球及其制备方法
CN113164382A (zh) * 2018-12-04 2021-07-23 万达制药公司 伊潘立酮的贮库施用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
CA2316052C (en) * 1989-07-07 2008-09-02 David Bodmer Sustained release formulations of water soluble peptides
FI106926B (fi) * 1989-07-07 2001-05-15 Novartis Ag Menetelmä pitkäaikaisesti vapautuvan koostumuksen muodostamiseksi
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
IE960308A1 (en) * 1996-04-23 1997-11-05 Kinerton Ltd Sustained release ionic conjugate
AU5678398A (en) * 1997-01-29 1998-08-18 Takeda Chemical Industries Ltd. Sustained-release microspheres, their production and use
EP1240896A3 (en) 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
MY158342A (en) * 2003-11-14 2016-09-30 Novartis Ag Pharmaceutical composition
GB0326602D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
KR20060118504A (ko) * 2003-11-25 2006-11-23 노파르티스 아게 소마토스타틴 유사체 치료법의 효능에 대한 바이오마커

Also Published As

Publication number Publication date
CL2008001509A1 (es) 2009-05-08
DOP2009000262A (es) 2010-10-15
AU2008252931B2 (en) 2011-09-01
CU24028B1 (es) 2014-10-02
TWI412373B (zh) 2013-10-21
ECSP099793A (es) 2010-01-29
US9351923B2 (en) 2016-05-31
TW200906437A (en) 2009-02-16
KR20160002937A (ko) 2016-01-08
ZA200907168B (en) 2010-07-28
US20130129798A1 (en) 2013-05-23
US20100178344A1 (en) 2010-07-15
PA8781501A1 (es) 2008-12-18
CA2683935A1 (en) 2008-11-27
CR11078A (es) 2009-12-04
NZ580589A (en) 2011-12-22
GEP20125582B (en) 2012-07-25
NI200900207A (es) 2010-09-07
JP5507447B2 (ja) 2014-05-28
CN101677965B (zh) 2015-09-09
JP2010527971A (ja) 2010-08-19
KR101930588B1 (ko) 2018-12-18
MY148915A (en) 2013-06-14
CA2683935C (en) 2016-07-19
EA018203B1 (ru) 2013-06-28
SMAP200900099A (it) 2010-01-19
CO6241097A2 (es) 2011-01-20
HUE046490T2 (hu) 2020-03-30
MA31445B1 (fr) 2010-06-01
WO2008142153A1 (en) 2008-11-27
CU20090200A7 (es) 2011-09-21
SV2009003421A (es) 2010-05-21
EA200901523A1 (ru) 2010-04-30
DK2164473T3 (da) 2019-12-16
EP3666263A1 (en) 2020-06-17
UA97396C2 (ru) 2012-02-10
HN2009003296A (es) 2014-02-10
ES2761227T3 (es) 2020-05-19
TN2009000447A1 (en) 2011-03-31
IL201571A0 (en) 2010-05-31
CN101677965A (zh) 2010-03-24
AU2008252931A1 (en) 2008-11-27
GT200900302A (es) 2011-07-01
PT2164473T (pt) 2019-12-11
ME00955B (me) 2012-06-20
AR066677A1 (es) 2009-09-02
IL201571B (en) 2018-11-29
EP2164473A1 (en) 2010-03-24
SMP200900099B (it) 2010-11-12
BRPI0811904A2 (pt) 2014-11-18
KR20100017904A (ko) 2010-02-16
EP2164473B1 (en) 2019-09-11
PE20090387A1 (es) 2009-04-28
PL2164473T3 (pl) 2020-07-27
MX2009012536A (es) 2009-12-03
SI2164473T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
UY31103A1 (es) Composiciones farmaceuticas en base a microparticulas comprendiendo un analogo de somatostatina, proceso de preparacion y aplicaciones
ATE528989T1 (de) Kristalline feste rasagilin-base
UA94942C2 (ru) Фармацевтические композиции с ингибиторами dpp iv
UY30931A1 (es) Amidas de 4-aril-1,4-dihidro-1,6-naftiridina sustituidas y su uso
GT201200250A (es) Ariltriazolonas ligadas a bisarilo y su uso
UY29839A1 (es) Ácidos fenoxiaceticos sustituidos, composiciones farmacéuticas conteniéndolos, procesos para su preparación y aplicaciones.
EA200802008A1 (ru) Фармацевтические композиции
GT200600084A (es) Forma cristalina beta de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
ECSP066376A (es) FORMA CRISTALINA GAMMA-d DEL CLORHIDRATO DE IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
UY29079A1 (es) Acidos fenoxiacéticos sustituidos, composiciones que los contienen, procedimientos de preparación y aplicaciones
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
BRPI0408848B8 (pt) composições farmacêuticas de complexo de ciclodextrina-cladribina complexo, usos do referido complexo, bem como processos para a sua preparação
GT200500130A (es) Forma cristalina alfa del ranelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen
EA201590790A1 (ru) СТАБИЛЬНАЯ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ PEG-ИНТЕРФЕРОНА АЛЬФА-2b
ATE552832T1 (de) Antidepressivum-propharmaka
ECSP088472A (es) Derivados de 9-cloro-15-desoxiprostaglandina, procesos para su preparación y su uso como medicamento
GT200500358A (es) Compuestos organicos
UY32081A (es) Nuevas heteroarilcarboxamidas, su preparación y su uso como medicamentos
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
DOP2006000024A (es) Tiazolidinonas, su preparación y su uso como medicamento

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20171109